Valuation
- Market cap
- 0
- Revenue TTM
- $2,200,000
- Net income TTM
- $-37,880,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -1,721.82%
- Debt to equity
- 0.00
Trading
- Volume
- 400
- Avg volume
- 2,370
- Day's range
- $0.00 – $0.00
- Shares out
- 372,000
- Stochastic %K
- 50%
- Beta
- 0.72
- Analysts
- —
- Price target
- —
Company profile
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and...
Show more
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 646 293 2100
- Website
- https://seelostherapeutics.com
- Address
- 300 Park Avenue, 2nd Floor, New York, United States
Latest news
No headlines yet.
